Today: 7 February 2026
Subscribe
Browse Category

NYSE:PFE News 30 December 2025 - 3 January 2026

Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

NEW YORK, Jan 2, 2026, 20:13 ET — Market closed Johnson & Johnson shares ended Friday up 0.19% at $207.35 after the healthcare company said its board declared a $1.30-per-share cash dividend for the first quarter of 2026. Yahoo Finance The timing matters because investors entered 2026 with markets trying to stabilize after a late-December stretch that failed to deliver the usual year-end “Santa Claus” bounce. Wall Street’s focus is shifting back to interest-rate expectations and the next round of economic data. Reuters For income-focused investors, dividends can act as a buffer in volatile tape because they provide a cash
3 January 2026
·····
Pfizer stock rises today as 2026 drug price hikes grab headlines again — what PFE investors are watching

Pfizer stock rises today as 2026 drug price hikes grab headlines again — what PFE investors are watching

NEW YORK, January 2, 2026, 13:56 ET — Regular session Pfizer Inc shares rose 0.8% to $25.09 on Friday, as investors digested renewed attention on U.S. drug pricing and early-year list-price changes. The timing matters. January is when drugmakers typically reset U.S. prices, and the moves can quickly become a political and regulatory flashpoint — especially as the Trump administration keeps pressing for lower costs. For Pfizer, pricing headlines also land as the company tries to stabilize revenue after pandemic-era demand faded. Investors are sensitive to anything that could trigger tougher scrutiny or force steeper discounts. List price is the
2 January 2026
···
Pfizer stock slips before the bell as 2026 drug price hikes put PFE back in focus

Pfizer stock slips before the bell as 2026 drug price hikes put PFE back in focus

NEW YORK, Jan 2, 2026, 09:18 ET — Premarket Pfizer Inc shares fell 0.4% to $24.90 in premarket trading on Friday after a Reuters report said the drugmaker plans to raise U.S. list prices on around 80 medicines in 2026. Reuters The pricing moves matter now because January is when drugmakers typically reset U.S. list prices, a closely watched “sticker price” that can shape political scrutiny and payer negotiations. They also land as the Trump administration presses manufacturers to lower U.S. drug costs, putting any annual price round under a brighter spotlight than in prior years. A drug’s list price
2 January 2026
···
Pfizer stock today: PFE slips as report flags 2026 U.S. drug price hikes

Pfizer stock today: PFE slips as report flags 2026 U.S. drug price hikes

NEW YORK, January 1, 2026, 20:51 ET — Market closed Pfizer Inc (PFE) shares last traded at $24.90, down 0.4% from the previous close, with U.S. markets closed on Thursday for the New Year’s Day holiday. Reuters reported Pfizer is leading a new round of U.S. list-price increases for 2026, planning hikes on around 80 drugs and vaccines — including a 15% rise for its COVID-19 shot Comirnaty — as drugmakers overall line up price increases on at least 350 branded medicines, with a median hike of about 4%. “They really just nibble around the margins,” said Dr. Benjamin Rome,
2 January 2026
····
Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes

Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes

NEW YORK, January 1, 2026, 06:48 ET — Market closed Pfizer Inc shares were last indicated slightly lower after hours on Wednesday after a report said the drugmaker plans to raise U.S. list prices on about 80 medicines in 2026. U.S. stock markets were closed on Thursday for the New Year’s Day holiday. (Reuters) Why it matters now: January is the industry’s main reset point for annual drug pricing, and the moves land as Washington keeps drug costs in the political crosshairs. Investors often read fresh price actions as both a revenue lever and a regulatory risk flag. The headline
1 January 2026
····
Pfizer stock today: PFE in focus as 2026 U.S. drug price hikes kick off — what to watch next

Pfizer stock today: PFE in focus as 2026 U.S. drug price hikes kick off — what to watch next

NEW YORK, January 1, 2026, 05:20 ET — Market closed. Pfizer Inc (NYSE:PFE) is in focus after annual U.S. drug pricing changes for 2026 included increases on some of its medicines, a politically sensitive topic heading into the new year. Pfizer shares last closed down 0.36% at $24.90 on Wednesday after trading between $24.88 and $25.02, with about 29.4 million shares changing hands. The price resets typically arrive on Jan. 1, when manufacturers post higher list prices — the sticker price before rebates — for many branded drugs. This year’s round is landing as the Trump administration keeps pressure on
1 January 2026
··
Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

NEW YORK, December 31, 2025, 18:50 ET — After-hours Pfizer Inc. shares fell about 0.4% to $24.90 in after-hours trading on Wednesday, after a report said the drugmaker is leading a wave of U.S. list-price increases set for 2026. The data, compiled by healthcare research firm 3 Axis Advisors, showed drugmakers plan hikes on at least 350 branded medicines, with Pfizer accounting for around 80 increases, including a 15% rise for its COVID vaccine Comirnaty. “They really just nibble around the margins,” said Dr. Benjamin Rome, a health policy researcher at Brigham and Women’s Hospital in Boston. Reuters The timing
1 January 2026
····
Pfizer stock today: PFE slips after report on 2026 U.S. drug price hikes

Pfizer stock today: PFE slips after report on 2026 U.S. drug price hikes

NEW YORK, December 31, 2025, 14:53 ET — Regular session Pfizer shares were down 0.1% at $24.96 in afternoon trade on Wednesday after a Reuters report said the drugmaker plans U.S. list-price hikes on about 80 medicines in 2026. Reuters The planned increases, set to start Jan. 1, land at a sensitive moment for drug pricing as the Trump administration presses the industry to lower costs. Annual list-price resets can also shape negotiations with insurers and the political risk premium investors apply to large drugmakers. Pfizer’s own outlook has put a spotlight on revenue durability. In its December guidance, Pfizer
31 December 2025
····
Pfizer stock flat before the bell as report flags 2026 U.S. drug price hikes, including 15% Comirnaty rise

Pfizer stock flat before the bell as report flags 2026 U.S. drug price hikes, including 15% Comirnaty rise

NEW YORK, December 31, 2025, 08:51 ET — Premarket Pfizer Inc shares were little changed in premarket trading on Wednesday after a report showed the drugmaker is leading a new round of U.S. list-price increases for 2026. The stock was down about 0.02% at $24.99, after closing Tuesday at roughly $25.00. The issue matters now because drug pricing has returned to the front burner in Washington, with the Trump administration pressing manufacturers to rein in costs. Year-end is also when many companies set list-price changes that typically take effect in early January. For investors, higher list prices can support revenue
31 December 2025
·····
Pfizer stock flat after hours as TD Cowen sticks with Hold; Feb. 3 results ahead

Pfizer stock flat after hours as TD Cowen sticks with Hold; Feb. 3 results ahead

NEW YORK, December 30, 2025, 19:40 ET — After-hours Pfizer Inc. shares were little changed in late after-hours trading on Tuesday, down about 0.02% at $24.99, after moving between $24.92 and $25.10 in the regular session. After-hours trading is the session after the 4 p.m. ET close, when volumes can be thinner and moves can be sharper. The quiet tape does not mean investors have gone quiet on Pfizer. Traders have been treating the stock as a test case for whether Big Pharma can defend cash flows as pandemic-era sales fade and older blockbusters face cheaper rivals. That backdrop has
31 December 2025
···
Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

NEW YORK, December 30, 2025, 13:50 ET — Regular session Pfizer Inc (NYSE:PFE) shares were up about 0.1% at $25.03 in afternoon trading on Tuesday, after moving between $24.92 and $25.10. TD Cowen reiterated its Hold rating and kept a $30 price target, pointing to negative trends in its model through 2030 despite the stock’s dividend yield near 7%. Investing.com The call lands as investors weigh Pfizer’s latest 2026 targets after the drugmaker projected revenue of $59.5 billion to $62.5 billion next year and adjusted earnings of $2.80 to $3.00 a share. “Adjusted” earnings strip out certain items the company
30 December 2025
····
Pfizer stock today: PFE holds near $25 as year-end trading turns to Fed minutes and next earnings

Pfizer stock today: PFE holds near $25 as year-end trading turns to Fed minutes and next earnings

NEW YORK, December 30, 2025, 03:31 ET — Market closed Pfizer Inc (PFE) shares were last down 0.3% at $25.00 in after-hours trading, after ending Monday at $25.09. The stock traded between $24.98 and $25.19 in the regular session. With U.S. markets in the final stretch of the year, volumes typically thin and position-adjusting can drive short-term moves. That leaves investors leaning more on the next clear catalyst than on day-to-day headlines. Wall Street’s main indexes ended lower on Monday as megacap tech shares retreated, and traders have the minutes from the Federal Reserve’s last meeting and weekly jobless claims
30 December 2025
····
1 … 3 4 5 6 7 … 11

Stock Market Today

Go toTop